ID Source | ID |
---|---|
PubMed CID | 173203 |
MeSH ID | M0083133 |
Synonym |
---|
pyroglutaminyl-seryl-leucinamide |
(2s)-n-[(2s)-1-[[(2s)-1-amino-4-methyl-1-oxopentan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]-5-oxopyrrolidine-2-carboxamide |
trh-an |
pyro-gln-ser-leu-amide |
pyroglutamylserylleucinamide |
pyr-ser-leu-nh2 |
l-leucinamide, 5-oxo-l-prolyl-l-seryl- |
73684-80-7 |
pyroglutamine-serine-leucinamide |
DTXSID00223954 |
pyroglutamyl-seryl-leucinamide |
(s)-n-((s)-1-(((s)-1-amino-4-methyl-1-oxopentan-2-yl)amino)-3-hydroxy-1-oxopropan-2-yl)-5-oxopyrrolidine-2-carboxamide |
AKOS040753664 |
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 1 (100.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.66) All Compounds (24.57) |
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 0 (0.00%) | 5.53% |
Reviews | 0 (0.00%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 5 (100.00%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |